Dr. Lee pioneered the translation of gene discoveries into
therapies for both rare and common diseases. He identified the
first human mutations in dwarfism (in COL2A1) and Marfan syndrome
(in Fibrillin), and then in the master transcriptional factors
(RUNX2 and LMX1B) that regulate these matrix proteins during
skeletal differentiation and patterning. He then showed how
dysregulation of post‐translational modification of collagens
causes osteogenesis imperfecta (OI) leading to the discovery of
over 18 new genetic causes of OI. He showed that increased TGFb
signaling is a common driver in OI and he is testing this in a
clinical trial by the NIH Brittle Bone Disorders Consortium.
Studying matrix-cell signaling in bone, he identified WNT1 as the
key WNT regulating human bone mass in dominant, early-onset
osteoporosis and in recessive OI, co-led the first clinical trial
of anabolic therapy in OI, and identified Notch requirements in
bone homeostasis and its dysregulation as a driver of osteosarcoma
and breast cancer metastasis. He developed a gene therapy approach
for the osteoarthritis in chondrodysplasias and this is now
licensed for testing in the first human in vivo gene therapy trial
in age-related osteoarthritis. In the area of genomic medicine, he
is leading the application of whole genome and RNA sequencing
technologies to the evaluation of undiagnosed disease in the NIH
Undiagnosed Diseases Network.
We are seeking a Postdoctoral Associate with experience in
preferably in mouse genetics and skeletal biology (although not
required). The position will perform mouse genetic and cell
biological studies into the mechanisms of how mutations causing
human skeletal dysplasias affect bone, cartilage, and tendon
development and homeostasis. Mouse genetics as well as induced
pluripotent stem cells will be used to model human mutations.
Current disease models under study include brittle bone disease or
Osteogenesis imperfecta. The position will study impact of these
mutations on osteoblast, osteoclast, chondrocyte, and tenocyte
development and homeostasis. In addition, the Postdoctoral
Associate will study how matrix mutations alter signaling to
progenitor or skeletal stem cells.
- Plans, directs and conducts specialized and advanced research
- Evaluates and analyzes data.
- May establish new research protocols and procedures.
- Summarizes research findings and publish results in research
- May be responsible for laboratory operations.
- May supervise research staff.
- MD or Ph.D. in Basic Science, Health Science, or a related
- No experience required.
Baylor College of Medicine is an Equal Opportunity/Affirmative
Action/Equal Access Employer.